Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

► No direct evidence exists for effectiveness of the new serotypes covered by PCV13. ► Efficacy was presumed via a putative serological correlate of protection. ► One dose of PCV13 showed 70% efficacy against IPD caused by new serotypes. ► Protection also demonstrated against individual serotypes for 7F and 19A. ► 50% less IPD in children <2 years from one of the new serotypes since introduction.